{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:15:02Z","timestamp":1788149702284,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10675-7","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:45:31Z","timestamp":1788147931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trials and tribulations of spironolactone in heart failure with preserved ejection fraction: Insights from the SPIRIT-HF trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Christian","family":"Basile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Keramida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiria","family":"Liori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Kapelios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishay","family":"Grupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"10675_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","volume":"21","author":"MS Khan","year":"2024","unstructured":"Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J (2024) Global epidemiology of heart failure. Nat Rev Cardiol 21:717\u2013734. https:\/\/doi.org\/10.1038\/s41569-024-01046-6","journal-title":"Nat Rev Cardiol"},{"key":"10675_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","volume":"23","author":"A Uijl","year":"2021","unstructured":"Uijl A, Savarese G, Vaartjes I, Dahlstr\u00f6m U, Brugts JJ, Linssen GCM et al (2021) Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail 23:973\u2013982. https:\/\/doi.org\/10.1002\/ejhf.2169","journal-title":"Eur J Heart Fail"},{"key":"10675_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10741-025-10524-z","volume":"30","author":"AE Rafei","year":"2025","unstructured":"Rafei AE, Harrington JA, Tavares CAM, Guimar\u00e3es PO, Ambrosy AP, Bonaca MP et al (2025) Heart failure with preserved ejection fraction therapeutics: in search of the pillars. Heart Fail Rev 30:1005\u20131014. https:\/\/doi.org\/10.1007\/s10741-025-10524-z","journal-title":"Heart Fail Rev"},{"key":"10675_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS et al (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404:1119\u20131131. https:\/\/doi.org\/10.1016\/s0140-6736(24)01733-1","journal-title":"Lancet"},{"key":"10675_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.2952","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Girerd N, Duarte K, Ferreira JP, McMurray JJV, van Veldhuisen DJ et al (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial. Eur J Heart Fail 25:1444\u20131449. https:\/\/doi.org\/10.1002\/ejhf.2952","journal-title":"Eur J Heart Fail"},{"key":"10675_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"10675_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G et al (2017) Spironolactone metabolites in TOPCAT - New insights into regional variation. N Engl J Med 376:1690\u20131692. https:\/\/doi.org\/10.1056\/NEJMc1612601","journal-title":"N Engl J Med"},{"key":"10675_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.114.013637","volume":"131","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Zannad F (2015) Regional differences in heart failure with preserved ejection fraction trials. Circulation 131:7\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013637","journal-title":"Circulation"},{"key":"10675_CR9","volume-title":"Deutsches Zentrum f\u00fcr H-K-F, Echo Core Lab B, University of G","author":"G University Medicine","year":"2019","unstructured":"Spironolactone in the Treatment of Heart Failure- a Double-blind, Randomized, Placebo-controlled, University Medicine G (2019) Parallel group interventional phase III study to determine efficacy and safety of spironolactone on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid-range or preserved ejection fraction. Deutsches Zentrum f\u00fcr H-K-F, Echo Core Lab B, University of G. Ludwig-Maximilians - University of M, Institute for Cardiovascular Computer-assisted Medicine C et al. (eds)"},{"key":"10675_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ejhf.1351","volume":"21","author":"CN Marti","year":"2019","unstructured":"Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ et al (2019) Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. Eur J Heart Fail 21:286\u2013296. https:\/\/doi.org\/10.1002\/ejhf.1351","journal-title":"Eur J Heart Fail"},{"key":"10675_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/circulationaha.124.072855","volume":"151","author":"C Basile","year":"2025","unstructured":"Basile C, Lindberg F, Benson L, Guidetti F, Dahlstr\u00f6m U, Piepoli MF et al (2025) Withdrawal of guideline-directed medical therapy in patients with heart failure and improved ejection fraction. Circulation 151:931\u2013945. https:\/\/doi.org\/10.1161\/circulationaha.124.072855","journal-title":"Circulation"},{"key":"10675_CR12","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","volume":"26","author":"LH Lund","year":"2024","unstructured":"Lund LH, James S, DeVore AD, Anstrom KJ, Fudim M, Aaronson KD et al (2024) The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): rationale and design. Eur J Heart Fail 26:2453\u20132463. https:\/\/doi.org\/10.1002\/ejhf.3453","journal-title":"Eur J Heart Fail"},{"key":"10675_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10741-024-10462-2","volume":"30","author":"R Halaseh","year":"2025","unstructured":"Halaseh R, Sauer AJ, Vardeny O, Canonico ME, Harrington J, Svetlichnaya J et al (2025) A fine addition: finerenone in the evolving landscape of heart failure with preserved ejection fraction. Heart Fail Rev 30:287\u2013291. https:\/\/doi.org\/10.1007\/s10741-024-10462-2","journal-title":"Heart Fail Rev"},{"key":"10675_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"10675_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102637","volume":"13","author":"JL Harrington","year":"2025","unstructured":"Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M et al (2025) Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. JACC Heart Fail 13:102637. https:\/\/doi.org\/10.1016\/j.jchf.2025.102637","journal-title":"JACC Heart Fail"},{"key":"10675_CR16","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-r","volume":"102","author":"I Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C et al (1992) Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102:1680\u20131685. https:\/\/doi.org\/10.1016\/0016-5085(92)91730-r","journal-title":"Gastroenterology"},{"key":"10675_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","volume":"36","author":"PI Georgianos","year":"2023","unstructured":"Georgianos PI, Agarwal R (2023) The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens 36:135\u2013143. https:\/\/doi.org\/10.1093\/ajh\/hpac124","journal-title":"Am J Hypertens"},{"key":"10675_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s40262-023-01312-9","volume":"62","author":"R Heinig","year":"2023","unstructured":"Heinig R, Eissing T (2023) The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone. Clin Pharmacokinet 62:1673\u20131693. https:\/\/doi.org\/10.1007\/s40262-023-01312-9","journal-title":"Clin Pharmacokinet"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10675-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:45:32Z","timestamp":1788147932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10675-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10675"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10675-7","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable\n                      .","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs Canonico receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that currently receives or has recently received grants or funding from the following organizations or their affiliates: 35Pharma, Inc., Abbott Laboratories, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Amgen, Inc., Arrowhead Pharmaceuticals, AstraZeneca Pharmaceuticals Ltd, Autonomy Bio, Inc., Bayer Pharmaceuticals, Inc., Bristol-Myers Squibb, Inc., Cleerly, Inc., CSL Behring, Inc., Eidos Therapeutics, Inc., EluraBio, Inc, Esperion Therapeutics, Inc., Faraday Pharmaceuticals, Inc., Gasherbrum Bio, Inc., Insmed, Inc., IsomAb Limited, Johnson & Johnson, Inc., Lexicon Pharmaceuticals, Inc., Lilly USA, LLC, Medison Pharma, Inc., Merck Sharp & Dohme Corp., Meridian Bioscience, Nectero Medical, Inc., NewAmsterdam Pharma, Novartis Pharmaceuticals Corporation, Novo Nordisk, Inc., Pfizer, Inc., Prothena Biosciences, Ltd., Regeneron, Inc., Roche Holdings AG, Sanofi, Inc., Silence Therapeutics PLC, Stealth BioTherapeutics Inc., Tourmaline Bio, Inc., VarmX, Inc., Viz.ai, Inc. and Verve Therapeutics, Inc. CPC has rights to acquire equity in Airseal CardioVascular, Inc.Dr. Mario Enrico Canonico is an Editorial Board Member of Heart Failure Reviews.Dr Chris J. Kapelios reports honoraria from Abbott, AstraZeneca and Bayer. He is an Editorial Board Member of Heart Failure Reviews.Dr. Farmakis reports lecture or advisory board honoraria, trial committee membership or grants from Abbott, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Leo, Roche, Zoll, and research grants from the European Union.Dr Kalliopi Keramida reports honoraria from Leo Pharmaceuticals Hellas and Glaxo SmithKline, She is an Editorial Board Member of Heart Failure Reviews.Dr Monzo received a travel grant from Boehringer.The other authors have nothing to declare.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}